Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada; Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada.
Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
Trends Microbiol. 2014 Aug;22(8):456-63. doi: 10.1016/j.tim.2014.04.002. Epub 2014 Apr 30.
Filovirus infections cause fatal hemorrhagic fever characterized by the initial onset of general symptoms before rapid progression to severe disease; the most virulent species can cause death to susceptible hosts within 10 days after the appearance of symptoms. Before the advent of monoclonal antibody (mAb) therapy, infection of nonhuman primates (NHPs) with the most virulent filovirus species was fatal if interventions were not administered within minutes. A novel nucleoside analogue, BCX4430, has since been shown to also demonstrate protective efficacy with a delayed treatment start. This review summarizes and evaluates the potential of current experimental candidates for treating filovirus disease with regard to their feasibility and use in the clinic, and assesses the most promising strategies towards the future development of a pan-filovirus medical countermeasure.
丝状病毒感染会导致致命性出血热，其特征是在迅速发展为严重疾病之前，最初会出现全身症状；最具毒性的物种可导致易感宿主在出现症状后 10 天内死亡。在单克隆抗体 (mAb) 治疗出现之前，如果在数分钟内不进行干预，感染最具毒性的丝状病毒物种的非人类灵长类动物（NHPs）会致命。此后，一种新型核苷类似物 BCX4430 也显示出具有延迟治疗开始的保护效力。本综述总结和评估了目前用于治疗丝状病毒病的实验候选药物在临床应用中的可行性和潜力，并评估了针对未来开发泛丝状病毒医疗对策最有前途的策略。
